Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. / Larsen, Philip J; Holst, Jens Juul.
In: Regulatory Peptides, Vol. 128, No. 2, 2005, p. 97-107.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
AU - Larsen, Philip J
AU - Holst, Jens Juul
N1 - Keywords: Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Neurotransmitter Agents; Peptide Fragments; Proglucagon; Protein Precursors
PY - 2005
Y1 - 2005
N2 - The interest in glucagon-like petide-1 (GLP-1) and other pre-proglucagon derived peptides has risen almost exponentially since seminal papers in the early 1990s proposed to use GLP-1 agonists as therapeutic agents for treatment of type 2 diabetes. A wealth of interesting studies covering both normal and pathophysiological role of GLP-1 have been published over the last two decades and our understanding of GLP-1 action has widened considerably. In the present review, we have tried to cover our current understanding of GLP-1 actions both as a peripheral hormone and as a central neurotransmitter. From an initial focus on glycaemic control, GLP-1 research has been diverted to study its role in energy homeostasis, neurodegeneration, cognitive functions, anxiety and many more functions. With the upcoming introduction of GLP-1 agonists on the pharmaceutical venue, we have witnessed an outstanding example of how initial ideas from basic science laboratories have paved their way to become a novel therapeutic strategy to fight diabetes.
AB - The interest in glucagon-like petide-1 (GLP-1) and other pre-proglucagon derived peptides has risen almost exponentially since seminal papers in the early 1990s proposed to use GLP-1 agonists as therapeutic agents for treatment of type 2 diabetes. A wealth of interesting studies covering both normal and pathophysiological role of GLP-1 have been published over the last two decades and our understanding of GLP-1 action has widened considerably. In the present review, we have tried to cover our current understanding of GLP-1 actions both as a peripheral hormone and as a central neurotransmitter. From an initial focus on glycaemic control, GLP-1 research has been diverted to study its role in energy homeostasis, neurodegeneration, cognitive functions, anxiety and many more functions. With the upcoming introduction of GLP-1 agonists on the pharmaceutical venue, we have witnessed an outstanding example of how initial ideas from basic science laboratories have paved their way to become a novel therapeutic strategy to fight diabetes.
U2 - 10.1016/j.regpep.2004.08.026
DO - 10.1016/j.regpep.2004.08.026
M3 - Journal article
C2 - 15780429
VL - 128
SP - 97
EP - 107
JO - Regulatory Peptides
JF - Regulatory Peptides
SN - 0167-0115
IS - 2
ER -
ID: 8418083